Life or Death Politics: The Fight to Keep Insulin Affordable
Repealing the Inflation Reduction Act risks millions of lives by undoing vital drug pricing caps.
The battle over insulin pricing in the United States has long been a flashpoint in the nation’s healthcare debate. Millions of Americans rely on insulin to manage diabetes, a life-threatening condition if untreated. Yet, pharmaceutical companies have continued to charge exorbitant prices for this life-saving drug, making insulin in the U.S. more expensive than in 32 other high-income nations. In response, the Inflation Reduction Act (IRA) under President Biden implemented a $35 cap on out-of-pocket insulin costs for Medicare beneficiaries. This bill was a step toward alleviating the financial burden on millions of Americans, particularly older adults living on fixed incomes. However, the Republican Party’s efforts to repeal this provision announced recently reveal a troubling prioritization of partisan politics and industry interests over the health and well-being of ordinary Americans.
A Lifeline for Millions
The IRA’s $35 insulin cap, effective January 1, 2025, offers a critical financial reprieve to an estimated 3.3 million Medicare beneficiaries who rely on insulin. Coupled with a broader cap on annual out-of-pocket Medicare Part D expenses set at $2,000, these measures reflect a commitment to making healthcare more affordable. For a population where one in three beneficiaries has diabetes, these changes are not just helpful—they are transformative.
Yet, the Republican Party has moved to repeal the IRA in its entirety. Pennsylvania Representative Scott Perry, alongside 15 other House Republicans, introduced legislation to dismantle the law on January 3rd, just days after it went into effect. Such a move would reverse progress on prescription affordability and increase out-of-pocket healthcare costs for millions of Americans, with devastating consequences for public health.
A Pattern of Obstruction
The opposition to insulin caps is not new. During the legislative debates leading up to the IRA’s passage, Senate Republicans blocked a proposed $35 insulin cap for privately insured Americans. The measure required 60 votes to pass, and despite bipartisan support from seven Republican senators, the effort fell short. The result: millions of privately insured Americans remain subject to insulin prices that are eight times higher than those in comparable nations.
Republicans justified their opposition by citing procedural rules, claiming the provision did not align with federal budget reconciliation requirements. While the procedural argument may hold water, it fails to address the larger ethical question: why deny affordable insulin to millions in need?
The Coffman Chronicle is powered by YOU—no billionaires, no corporate overlords. Help us keep exposing the BS, delivering sharp insights, and keeping you informed.
For just $8 a month or $80 a year, you can fuel the fight and be part of the movement .
Not ready to subscribe? No worries, chaos loves company, and you're always welcome. But if you’re fired up to keep us loud, proud, and unfiltered, smash that subscribe button now!
The Stakes of Repeal
Repealing the IRA would reintroduce the financial strain that the $35 insulin cap seeks to alleviate. For those on fixed incomes, the price of insulin can consume a significant portion of their budgets. Without caps, Americans have been forced to ration insulin, a dangerous practice that leads to preventable complications, hospitalizations, and even death.
Other prescription drugs are at risk due to their inclusion in the IRA. The law empowers Medicare to negotiate the prices of select high-cost medicines with the newest round announced this week. The provision aims to curb exorbitant pricing across the pharmaceutical industry, a pivotal prioritization of people over corporate profits. If repealed, millions of Americans would lose access to more affordable options for medications that treat cancer, heart disease, and other chronic conditions. These potential losses underscore the sweeping impact of the IRA and the high stakes of its repeal.
Diseases like heart disease and diabetes are not solely the result of lifestyle choices but are also strongly influenced by genetic factors. This reality is exacerbated by systemic issues, such as the lack of affordable healthy food, disproportionately affecting low-income communities. These compounding factors make affordable medication even more critical for managing chronic conditions and preventing severe health outcomes. The repeal of these measures would not only worsen health disparities but also deepen economic inequality, as low-income individuals and families disproportionately bear the burden of skyrocketing medical costs.
The repeal effort is further bolstered by conservative policy blueprints like Project 2025, which proposes undermining the IRA’s drug price negotiation mechanisms. These plans, aligned with pharmaceutical industry interests, prioritize ideological opposition to government intervention over constituents' urgent needs.
A Moral Imperative
Affordable insulin is not a luxury; it is a necessity. The $35 cap for Medicare beneficiaries represents a bipartisan acknowledgment that the status quo is unacceptable. However, the push to repeal these provisions exposes a glaring disconnect between Republican lawmakers and their constituents' everyday struggles. Rather than obstructing efforts to make healthcare more accessible, legislators should - at a bare minimum- focus on expanding these measures to include the privately insured. The price caps went into effect just weeks ago and are already under threat, demonstrating the degree to which some value the health of the people they represent.
Diabetes does not discriminate based on income or political affiliation. It affects millions of Americans, and affordable insulin is a matter of life and death. Repealing the IRA would be a step backward, leaving millions at the mercy of pharmaceutical companies that prioritize profits over people. It’s time for elected officials to prioritize the health of their constituents over partisan politics. Anything less is a dereliction of duty that politicians should pay for with their jobs, not our lives.
Sources: "Republicans block cap on insulin costs for many Americans from Democratic deal," Associated Press, August 2022; "Republicans move to repeal Inflation Reduction Act $35 cap on insulin in bill co-sponsored by Pennsylvania Representative Scott Perry," The Pennsylvania Independent, January 8, 2025; "Why did Republicans vote against the insulin cap?" Axios; Project 2025 details as cited from conservative policy proposals, The Heritage Foundation.